Key result
Diabetic neuropathy was not associated with significant differences in vagus nerve cross-sectional area compared to controls (left VN MD -0.02 mm2, P=0.95; right VN MD -0.39 mm2, P=0.28).
Why the study?
High-resolution ultrasonography of vagus nerve cross-sectional area may serve as a noninvasive biomarker for early diabetic autonomic neuropathy, but synthesized evidence was lacking.
Does ultrasonographic measurement of the vagus nerve cross-sectional area differ between patients with diabetic neuropathy and healthy controls?
Meta-Analysis (n=604)
Does ultrasonographic measurement of the vagus nerve cross-sectional area differ between patients with diabetic neuropathy and healthy controls?
Mean Difference: -0.02 (95% CI -0.8–0.75)
p-value: p=0.95
Ultrasonographic measurement of vagus nerve cross-sectional area does not show significant overall differences between diabetic neuropathy patients and controls, limiting its current utility as a standalone diagnostic biomarker.
Suggests vagus nerve ultrasound lacks diagnostic utility for diabetic neuropathy; challenges the hypothesis that structural.
Introduction: Diabetic neuropathy, a prevalent complication of diabetes mellitus (DM), often involves autonomic dysfunction, with the vagus nerve (VN) being an early target. High-resolution ultrasonography has emerged as a noninvasive tool to assess structural nerve changes, including cross-sectional area (CSA), as a potential biomarker for early diagnosis. This systematic review and meta-analysis, the first to synthesize evidence on VN CSA in diabetic neuropathy, evaluated its diagnostic utility and confounding factors. Methods: Following PRISMA guidelines, a comprehensive search of PubMed, Scopus, Embase, and Web of Science yielded six studies encompassing 604 participants (347 diabetic patients and 257 controls). Results: Pooled CSA showed no significant differences between diabetic neuropathy patients and controls for left VN (MD: −0.02 mm 2 , 95% CI: −0.80–0.75, P = 0.95) or right VN (MD: −0.39 mm 2 , 95% CI: −1.09–0.31, P = 0.28). However, excluding an outlier study revealed a significant right VN CSA increase in DM patients (MD: 0.26 mm 2 , P < 0.01). Subgroup analyses indicated significant CSA differences in patients with BMI <27 kg/m 2 , age >50 years, and DM duration <9 years. Substantial heterogeneity (I 2 > 95%) across studies underscores variability in ultrasound protocols and patient demographics. Discussion: While VN CSA alone may not suffice as a standalone diagnostic biomarker, its role in specific subgroups and combined with functional assessments warrants exploration. Standardized imaging protocols and longitudinal studies are needed to clarify its clinical utility and pathophysiological implications in diabetic autonomic neuropathy.
No takes yet. Share an insight, caveat, or question.
Kheradpishe et al. (2026) conducted a meta-analysis in Diabetic neuropathy (n=604). Diabetic neuropathy vs. Controls was evaluated on Left vagus nerve cross-sectional area (MD -0.02, 95% CI -0.80-0.75, p=0.95). Diabetic neuropathy was not associated with significant differences in vagus nerve cross-sectional area compared to controls (left VN MD -0.02 mm2, P=0.95; right VN MD -0.39 mm2, P=0.28).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: